Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Center of Excellence for External Drug Discovery

Division of GlaxoSmithKline PLC

Latest From Acea Pharmaceuticals Inc.

Pipeline Watch: Phase III Read-Outs For Ozanimod, Olaparib And Sapacitabine

Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.

Pipeline Watch Approvals

The University of California, at Irvine

Since 1990, UCI grew from 109th to 46th in industry-funded research. David Schetter, Director, Office of Technology Alliances believes it will crack the top 30 this year. The life sciences dominate UCI's research base.

Seed Appeal

Sanderling focuses on just a few deals at a time, investing at the seed stage only.
BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • GlaxoSmithKline PLC
  • Senior Management
  • Mark Strobeck, Ph.D., VP., Bus. Dev.
    Hugh Cowley, MD, SVP, Head of the CEEDD
  • Contact Info
  • Center of Excellence for External Drug Discovery
    Phone: (610) 270-5546
    2301 Renaissance Blvd.
    P.O. Box 61540 King of Prussia, PA 19406-2772